Hologic (NASDAQ:HOLX) Announces Earnings Results

Hologic (NASDAQ:HOLX) released its quarterly earnings data on Wednesday. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01, Zacks reports. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic updated its Q2 2025 guidance to 1.000-1.030 EPS and its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Performance

Hologic stock traded down $6.80 during mid-day trading on Thursday, hitting $66.01. The company had a trading volume of 3,364,647 shares, compared to its average volume of 2,320,972. Hologic has a 12-month low of $65.87 and a 12-month high of $84.67. The company has a market capitalization of $14.90 billion, a price-to-earnings ratio of 19.88, a P/E/G ratio of 2.35 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company’s fifty day moving average is $72.91 and its 200-day moving average is $77.95.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.88% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Nine research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $86.46.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.